Feed / INSM

Insmed Incorporated

INSM

Healthcare · 127.33 -1.2% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Insmed Incorporated's current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 3 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Company-1.2% todayVolume comparison unavailable
Market group0 of 3 activeMixed Growth Exposure · unavailable
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
  • INSM's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if INSM's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 3 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • INSM's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations327
Usable filing statements90
Verified relationships2
Evidence supporting the case
  • Latest annual revenue changed +66.7% year over year.
  • Operating margin changed +35.9 percentage points in the latest annual period.
  • Net margin changed +40.7 percentage points in the latest annual period.
Evidence challenging the case
  • Diluted shares increased 21.3% in the latest annual period.
  • Credit and interest rates has repeated adverse evidence across 3 filings.
Questions before a position
  • EV/sales is 450% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

127.33
6m-8.7%12m-13.5%24m—
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$188.5M+14.6%$-3.88+14.9%
2022-12-31$245.4M+30.2%$-3.91+9.7%
2023-12-31$305.2M+24.4%$-5.34+14.1%
2024-12-31$363.7M+19.2%$-5.57+16.8%
2025-12-31$606.4M+66.7%$-6.42+21.3%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesnegative · 3 filings
“This decrease was primarily due to a reduction in interest expense related to the redemptions of the outstanding 0.75% Convertible Senior Notes due 2028 (the 2028 Convertible Notes) in the second quarter of 2025 and the outstanding 1.75% Convertible Senior No…”
10-K · Feb 19, 2026 ↗

Valuation discipline

Descriptive valuation snapshot

Price/sales 41.8× · EV/sales 41.8×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

127.33-1.2% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for INSM. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for INSM. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind INSM

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AZNAstraZeneca PLCpartnerMay 7, 2026 ▾

“Brensocatib is a small molecule, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016.”

Depended on by

RGNXREGENXBIO Inc.competitorMar 5, 2026 ▾

“There are three principal competitive gene therapy products in clinical development from Solid Biosciences (SGT-003), Genethon (GNT0004), and Insmed (INS1201).”

Filing peers

LQDAKNSAAUPH

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

INSM is currently a Early Follower in the organic co-movement group Mixed Growth Exposure. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for INSM; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.